Calderasib
Investigational drug
Calderasib is an investigational new drug that is being developed by Merck Sharp & Dohme for the treatment of solid tumors. It targets tumors that express G12C mutated KRAS protein.
It has been awarded a breakthrough therapy designation by the U.S. Food and Drug Administration.
Sources and credits
This article is adapted from the Wikipedia article “Calderasib”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- Calderasib.svg by Vaccinationist, Public domain
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.